SS Innovations (SSII) Q1 2024 Earnings Report

SS Innovations International (SSII) reported a striking top-line acceleration for Q1 2024, with revenue of $6.85 million, up 353% year-over-year and 403% quarter-over-quarter. This surge underscores early adoption of SSII’s surgical robotics ecosystem, including products such as Mantra, Mudra, Maya, and the OMNI 3D HD visualization platform. However, the company remains deeply unprofitable at this stage, with EBITDA of -$2.54 million and net income of -$2.80 million for the quarter, reflecting heavy operating costs as it scales product development and commercialization.

From a profitability perspective, gross margin stands at 42.3% (gross profit of $2.90 million on revenue of $6.85 million), but operating expenses of $5.62 million—dominated by General and Administrative spend of $5.22 million and R&D spending of $0.40 million—trigger a sizable operating loss of $2.72 million and a net loss of $2.80 million. The company ended the quarter with roughly $6.90 million in cash and equivalents against total debt of $10.78 million, yielding a net debt position of $3.88 million. Liquidity remains modest: current ratio 1.26, quick ratio 0.87, and cash ratio 0.44.

The revenue growth trajectory is compelling for a pre-profit medical device start-up, but sustained profitability will hinge on continued revenue scale, gross margin expansion, and disciplined operating expense management. Management commentary is not captured in the provided transcript dataset, so forward-looking signals and strategic framing from leadership are not quantifiable here. Investors should monitor product adoption rates, regulatory milestones, key partnerships, and any additional funding needs as SSII navigates its path to scale in a competitive and capital-intensive market.